EMICIZUMAB DOSING IN CHILDREN AND ADULTS WITH HEMOPHILIA A: SIMULATING A USER-FRIENDLY AND COST-EFFICIENT REGIMEN.
Sign Up to like & getrecommendations! Published in 2021 at "Thrombosis and haemostasis"
DOI: 10.1055/a-1499-0030
Abstract: BACKGROUND When emicizumab is dosed according to label, clinicians are obligated to discard or overdose medication due to discrepancies between calculated dose and vial content. The aim of this study was to compose a cost-efficient… read more here.
Keywords: emicizumab dosing; cost; alternative dosing; cost efficient ... See more keywords
Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.
Sign Up to like & getrecommendations! Published in 2020 at "Thrombosis and haemostasis"
DOI: 10.1055/s-0040-1710315
Abstract: BACKGROUND Emicizumab prophylaxis is a promising treatment that reduces bleeding events in severely affected patients with hemophilia A (PwHA). It is anticipated that emicizumab could be similarly effective in mild/moderate PwHA (PwMHA) although this effect… read more here.
Keywords: min1; improves vivo; emicizumab improves; pwmha ... See more keywords
Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2115777
Abstract: Abstract Background and objective A cost-minimization model was developed to compare recombinant factor VIII Fc (rFVIIIFc) and emicizumab as prophylaxis for hemophilia A without inhibitors. Methods The model was based on 100 patients from the… read more here.
Keywords: recombinant factor; without inhibitors; cost; emicizumab ... See more keywords
Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.15525
Abstract: Activated protein C (APC) inactivates activated factor V (FVa) and moderates FVIIIa by restricting FV cofactor function. Emicizumab is a humanized anti‐FIXa/FX bispecific monoclonal antibody that mimicks FVIIIa cofactor function. In recent clinical trials in… read more here.
Keywords: protein; activated factor; activated protein; inactivation ... See more keywords
Laboratory issues in gene therapy and emicizumab
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.13976
Abstract: The treatment options for the haemostatic disorders, haemophilia A and haemophilia B, have progressed rapidly over the last decade. The introduction of extended half‐life recombinant factor VIII (FVIII) and factor IX (FIX) concentrates to replace… read more here.
Keywords: emicizumab; factor; laboratory issues; gene therapy ... See more keywords
Anti‐idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14662
Abstract: Emicizumab markedly shortens the activated partial thromboplastin time (aPTT), resulting in inaccurate measurements of procoagulant and anticoagulant factor activities. We have recently reported that mixtures of two different anti‐idiotype monoclonal antibodies against emicizumab (anti‐emicizumab‐mAbs) allow… read more here.
Keywords: procoagulant anticoagulant; anti idiotype; emicizumab; antibodies emicizumab ... See more keywords
Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy
Sign Up to like & getrecommendations! Published in 2023 at "Haemophilia"
DOI: 10.1111/hae.14755
Abstract: Since the approval by the EMA of emicizumab for the care of severe haemophilia A without inhibitor, most of the patients of our haemophilia treatment centre started this new treatment. Thanks to the setting of… read more here.
Keywords: without inhibitor; clinical perception; haemophilia without; emicizumab ... See more keywords
Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.15187
Abstract: As the first non‐factor replacement therapy for persons with congenital hemophilia A (PwcHA), emicizumab's safety profile is of particular interest to the community. read more here.
Keywords: mortality framework; application hemophilia; hemophilia mortality; safety ... See more keywords
Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2021-056922
Abstract: Introduction Subcutaneous emicizumab prophylaxis substantially reduces bleeding episodes in patients with haemophilia A (PwHA) and factor VIII inhibitor. However, thrombotic events occurred in some PwHA with inhibitor who had received high cumulative doses of activated… read more here.
Keywords: unebi study; coagulation; bypassing agents; inhibitor ... See more keywords
Management of Persons with Hemophilia A with Inhibitors After Emicizumab Approval
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116176
Abstract: Introduction: Emicizumab, a bispecific antibody to factors IXa/X, was approved by the Food and Drug Administration in 2017 for prophylactic treatment of persons with hemophilia A (PwHA) with inhibitors. Compared with other treatments for PwHA,… read more here.
Keywords: pwha inhibitors; treatment; management; emicizumab ... See more keywords
Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124421
Abstract: Introduction: The standard of care for patients with hemophilia A without inhibitors is factor VIII (FVIII) replacement therapy. The availability of non-factor therapy such as emicizumab (Hemlibra®; Genentech, Inc., South San Francisco, CA, USA) is… read more here.
Keywords: treatment; hemophilia without; prophylaxis; model ... See more keywords